|Day Low/High||1.07 / 1.13|
|52 Wk Low/High||0.93 / 3.26|
The most recent short interest data has been released for the 12/29/2017 settlement date, which shows a 1,746,022 share decrease in total short interest for Organovo Holdings Inc , to 15,136,112, a decrease of 10.34% since 12/15/2017. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.
The Summit, N.J.-based firm said Thursday that it was discontinuing the GED-0301 (mongersen) Phase 3 Revolve study in Crohn's disease and the extension trial.
Investors eyeing a purchase of Organovo Holdings Inc stock, but cautious about paying the going market price of $2.32/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the February 2018 put at the $2 strike, which has a bid at the time of this writing of 15 cents.
Shire, Bellicum Pharmaceuticals and Organovo Holdings were among the biotech stock movers in premarket trading on June 22.
Intra-Cellular Therapies, Organovo Holdings and Acorda Therapeutics were among the biotech stock movers in premarket trading on Monday.
Organovo, Endo and Omeros were among the biotech stock moves in premarket trading on Thursday.
The company's shares were up 24% ahead of market's open on an FDA approval.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.